Cluster Headaches and Psilocybin: What Nobody in Medicine Told Me
Cluster headaches are among the most painful conditions known to medicine. Here's what the psilocybin cluster headache community has learned over 20 years of self-reporting — and what the emerging research shows.
Cluster headaches are sometimes called 'suicide headaches' — a name given to them by the people who have them, not by doctors. They are classified as primary headache disorders and rated among the most painful experiences in medical literature. A cluster period can last weeks or months, with attacks occurring up to 8 times per day, each lasting 15 minutes to 3 hours. Standard treatments often fail.
I've had episodic cluster headaches since I was 24. I'm 39 now. In 2019, after a particularly bad cluster period where triptans and oxygen were insufficient, I found a forum called Cluster Busters. What I found there changed my life.
The Cluster Busters community has been self-experimenting with psilocybin for cluster headaches since the early 2000s. Their empirical observations, compiled before any formal research existed: sub-threshold doses of psilocybin (0.1–0.5g dried mushrooms) taken every 4–5 days can interrupt a cluster period and extend remission. The protocol requires specific timing to avoid psilocybin's own refractory period and any triptans taken previously.
I tried the protocol in January 2020. My cluster period ended within two weeks. My subsequent cluster period in 2021 was shorter than any I'd experienced before. I can't attribute this with certainty to the psilocybin — cluster headaches have natural variability — but the pattern is consistent with what others report.
In 2021, Yale published the first peer-reviewed case series on psilocybin for cluster headaches. In 2023, the first RCT enrolled at Yale. This is a legitimate area of research now, emerging from patient-led observation that preceded academic study by two decades.
More Experience Reports
Three years of talk therapy, one psilocybin session, and a fundamentally different relationship with anxiety. A first-timer's account of a licensed Oregon session.
Read →What happens when you underestimate a potent strain. A first-person account of a difficult experience, how the STOP protocol made the difference, and what emerged from the center of it.
Read →A Marine veteran with treatment-resistant PTSD reflects 60 days after participating in a university psilocybin clinical trial. The session didn't cure anything. But the relationship changed.
Read →